putamen

Introduction

Putamen is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

The putamen is the largest nucleus of the basal-ganglia and forms the lateral component of the dorsal striatum, together with the caudate-nucleus. Separated from the ^{1Citation1988 · DOI 10.1056/NEJM198804073181402Open reference} caudate by the internal capsule (except at their anterior connection in the fundus striati) and bounded laterally by the external capsule and claustrum, the putamen serves as the ^{2Citation2003 · PMID 14561615Open reference} primary input station for motor and sensorimotor information entering the basal ganglia circuit. It receives somatotopically organized projections from the primary motor-cortex, ^{3Citation2011 · DOI 10.3389/fnana.2011.00059Open reference} premotor cortex, supplementary motor area, and somatosensory cortex, as well as dense dopaminergic innervation from the substantia-nigra pars compacta (SNpc).^{4Citation1986 · DOI 10.1146/annurev.ne.09.030186.002041Open reference 5Citation1992 · PMID 1570304Open reference}

The putamen is of central importance in the pathophysiology of parkinsons, where it is the earliest and most severely affected striatal structure due to preferential ^{6Citation2025 · DOI 10.3389/fpsyt.2025.1647240Open reference} loss of dopaminergic projections from the ventrolateral tier of the SNpc. Posterior dorsal putamen shows the greatest dopamine depletion (up to 80% at symptom onset), making it ^{7Citation1990 · DOI 10.1016/0166-2236(90Open reference} the critical site of the motor circuit dysfunction that produces bradykinesia, rigidity, and tremor.^{1Citation1988 · DOI 10.1056/NEJM198804073181402Open reference} The putamen is also heavily affected in huntington-pathway, msa, ^{8Citation2005 · DOI 10.1073/pnas.0502762102Open reference} and other basal-ganglia disorders. ^{9Citation2024 · DOI 10.1093/braincomms/fcae409Open reference}

Anatomy

Location and Boundaries

The putamen occupies a lens-shaped (lenticular) position deep within the cerebral hemisphere: ^{2Citation2003 · PMID 14561615Open reference}0

• Medial boundary: External medullary lamina of the globus-pallidus, with which the putamen forms the lenticular (lentiform) nucleus

• Lateral boundary: External capsule, claustrum, and extreme capsule

• Superior boundary: White matter of the corona radiata

• Inferior boundary: Anterior commissure, nucleus-accumbens (ventral striatum)

• Anterior: Connected to the [caudate-nucleus head via cell bridges traversing the anterior limb of the internal capsule

• Posterior: Narrows and is bordered by the posterior limb of the internal capsule

The putamen measures approximately 5 cm in length along its anterior–posterior axis in the adult human brain and has a volume of roughly 4–6 ^{2Citation2003 · PMID 14561615Open reference}1 cm³ per hemisphere, as measured by high-resolution structural MRI.^{2Citation2003 · PMID 14561615Open reference}2 ^{2Citation2003 · PMID 14561615Open reference}3

Cellular Composition

Like the caudate-nucleus, the putamen is composed predominantly of: ^{2Citation2003 · PMID 14561615Open reference}4

• medium-spiny-neurons (MSNs): ~95% of all putaminal neurons. D1-expressing MSNs project directly to the globus pallidus internus (GPi)/substantia nigra pars reticulata (SNr) via the direct pathway (facilitating movement), while D2-expressing MSNs project to the globus pallidus externus (GPe) via the indirect pathway (inhibiting movement). The balance between these pathways is fundamentally disrupted in parkinsons due to dopamine depletion

• Cholinergic interneurons: Large aspiny neurons (~1–2%) that release acetylcholine and modulate MSN excitability. These tonically active neurons (TANs) pause their firing during reward-related and salient stimuli, contributing to reinforcement learning signals. They are relatively spared in early neurodegeneration

• GABAergic interneurons: pv-interneurons fast-spiking interneurons, sst-interneurons interneurons, and calretinin-positive interneurons that shape the temporal precision of MSN output

Striosome-Matrix Organization

The putamen, like the rest of the striatum, is organized into two biochemically and functionally distinct compartments: ^{2Citation2003 · PMID 14561615Open reference}5

• Striosomes (also called patches): Account for ~15% of striatal volume. Enriched in μ-opioid receptors, substance P, dopamine D1 receptors, and calretinin. Striosomes receive input primarily from limbic cortical areas (orbitofrontal cortex, insular-cortex, amygdala) and project to dopaminergic [neurons in the SNpc, forming a feedback loop that regulates dopamine release.^{2Citation2003 · PMID 14561615Open reference}6

• Matrix: The larger compartment (~85% of striatal volume). Enriched in calbindin, somatostatin, dopamine D2 receptors, and cholinergic markers. The matrix receives input from sensorimotor and associative cortices and projects to the GPi/GPe and SNr, forming the output channels of the classical basal ganglia motor circuit.

In MPTP-treated primate models of parkinsons, dopaminergic markers are more severely depleted in the matrix compartment of the posterior putamen, with relative ^{2Citation2003 · PMID 14561615Open reference}7 preservation of striosomal dopamine, suggesting compartment-specific vulnerability that may contribute to the preferential motor deficits ^{2Citation2003 · PMID 14561615Open reference}8 seen in PD.^{2Citation2003 · PMID 14561615Open reference}9 In depression, recent ^{3Citation2011 · DOI 10.3389/fnana.2011.00059Open reference}0 research has shown putaminal volume reductions accompanied by a shift from matrix-like to striosome-like structural connectivity patterns.^{3Citation2011 · DOI 10.3389/fnana.2011.00059Open reference}1

Somatotopic Organization

The putamen maintains a precise somatotopic organization that reflects its cortical inputs:

• Dorsal posterior putamen: Leg/trunk representation; receives input from supplementary motor area

• Dorsal middle putamen: Arm/hand representation; receives input from primary motor and premotor cortex

• Ventral putamen: Face/orofacial representation

• Anterior putamen: Associative/cognitive territory; receives input from prefrontal areas

This somatotopy is preserved in the output pathways through the globus-pallidus and thalamus, and is clinically relevant: the characteristic arm-dominant symptoms of early PD reflect the preferential dopamine depletion in the dorsal middle putamen.

Vascular Supply

The putamen receives its blood supply primarily from the lateral lenticulostriate arteries, branches of the middle cerebral artery (MCA). These end-arteries are particularly vulnerable to hypertensive damage, making the putamen the most common site of hypertensive intracerebral hemorrhage (accounting for ~35% of all spontaneous ICH). Lacunar infarcts from small vessel disease are also common in this region, contributing to vascular cognitive impairment and vascular parkinsonism.

Function

Motor Control

The putamen is the primary striatal structure involved in motor function. It processes motor commands through two parallel circuits:

1. Direct pathway (D1-MSN → GPi/SNr → thalamus → cortex): Facilitates desired movements by disinhibiting thalamo-cortical projections

2. Indirect pathway (D2-MSN → GPe → STN → GPi/SNr → thalamus → cortex): Suppresses unwanted movements by increasing inhibition of thalamo-cortical projections

dopamine from the substantia-nigra differentially modulates these pathways: it excites D1-MSNs (facilitating movement) and inhibits D2-MSNs (reducing movement suppression). The net effect of dopamine is to promote voluntary movement. Loss of putaminal dopamine in parkinsons leads to under-activation of the direct pathway and over-activation of the indirect pathway, producing the characteristic motor poverty (bradykinesia) and rigidity.^{3Citation2011 · DOI 10.3389/fnana.2011.00059Open reference}2

A third circuit, the hyperdirect pathway (cortex → subthalamic nucleus → GPi), bypasses the putamen entirely and provides rapid suppression of competing motor programs, important for action cancellation and impulse control.

Motor Learning and Habit Formation

The putamen is essential for stimulus-response learning (habit formation). While the caudate-nucleus mediates goal-directed, flexible behavior, the putamen stores well-learned motor programs that are executed automatically. This caudate-to-putamen shift during skill acquisition represents a transition from deliberate to automatic motor control.^{3Citation2011 · DOI 10.3389/fnana.2011.00059Open reference}3

A 2024 study demonstrated that motor learning is directly modulated by dopamine availability in the sensorimotor putamen: individuals with higher baseline putaminal dopamine capacity showed faster and more complete transitions from effortful to automatic motor execution.^{3Citation2011 · DOI 10.3389/fnana.2011.00059Open reference}4 This finding has implications for understanding why PD patients struggle to acquire and automate new motor skills.

In parkinsons, disruption of putaminal circuits forces patients to rely on frontal lobe-mediated conscious motor control, explaining why dual-tasking is particularly difficult and why well-learned motor sequences (e.g., walking, handwriting) deteriorate.

Reward Processing and Reinforcement Learning

Although the ventral striatum (nucleus accumbens) is most commonly associated with reward, the dorsal putamen plays a distinct role in action-reward contingency learning. Putaminal activity correlates with stimulus-action-dependent reward prediction — the learned association between specific motor actions and their outcomes — while the [caudate-nucleus tracks reward prediction errors (the discrepancy between expected and received reward).^{3Citation2011 · DOI 10.3389/fnana.2011.00059Open reference}5 This division underlies the putamen’s role in habit formation: as behaviors become habitual, reward processing shifts from caudate to putamen circuits.

Sensorimotor Integration

The putamen integrates sensory feedback with motor commands to fine-tune movement execution. It receives proprioceptive, tactile, and visual information from somatosensory and parietal cortex, which it combines with motor plans from frontal cortex to enable smooth, coordinated movement.

Neuroimaging

Structural Imaging

• Volumetric MRI: Putamen volume decreases with normal aging (~0.5% per year after age 60), but accelerated atrophy is observed in neurodegenerative conditions. In PD, putaminal atrophy correlates with motor severity and may serve as a progression biomarker. In huntington-pathway, putaminal atrophy is detectable up to 3 years before clinical onset.^{3Citation2011 · DOI 10.3389/fnana.2011.00059Open reference}6

• Quantitative MRI: Multiparametric quantitative MRI (T1, T2*, proton density, and magnetization transfer) reveals putaminal microstructural changes in PD, including increased iron content and altered tissue composition, even in early-stage disease. These microstructural gradients along the anterior–posterior axis of the putamen correspond to the known dopaminergic denervation pattern.^{3Citation2011 · DOI 10.3389/fnana.2011.00059Open reference}7

• Diffusion MRI: Diffusion tensor imaging shows changes in putaminal free water content in PD, reflecting neuronal loss and gliosis.

Functional Imaging

• DAT-SPECT: Dopamine transporter single-photon emission computed tomography (DaTscan) reveals reduced putaminal uptake as the most sensitive clinical imaging marker for PD diagnosis. The characteristic pattern is asymmetric reduction in posterior putaminal tracer binding, contralateral to the more affected side. DAT binding in the posterior putamen correlates with striatal dopamine levels and motor symptom severity.

• 18F-DOPA PET: Fluorodopa PET quantifies presynaptic dopaminergic function and shows posterior putaminal reductions paralleling DAT-SPECT findings.

• fMRI: Resting-state functional connectivity between the putamen and supplementary motor area (SMA) is enhanced in PD, interpreted as a compensatory mechanism to maintain motor function despite dopamine depletion.^{3Citation2011 · DOI 10.3389/fnana.2011.00059Open reference}8 Task-based fMRI shows reduced putaminal activation during motor sequence execution in PD, normalizing after levodopa administration.

Age-Related Changes

Graph theory analysis of resting-state fMRI has identified the putamen as one of the brain regions most affected by normal aging, showing altered functional connectivity patterns with cortical motor and prefrontal areas. These changes may underlie age-related declines in motor performance, processing speed, and habit learning capacity.^{3Citation2011 · DOI 10.3389/fnana.2011.00059Open reference}9

Role in Neurodegenerative Diseases

Parkinson’s Disease

The putamen is the epicenter of dopaminergic denervation in parkinsons and the primary driver of motor symptoms:

• Gradient of depletion: Post-mortem studies show that putaminal dopamine is depleted by 70–80% by the time motor symptoms emerge, following a posterior-to-anterior and dorsal-to-ventral gradient within the putamen. The posterior dorsal putamen (motor territory) is most affected; anterior ventral putamen (cognitive/limbic territory) is relatively spared early on. This gradient is more severe than in the caudate-nucleus, where depletion reaches only ~40% at symptom onset.^{4Citation1986 · DOI 10.1146/annurev.ne.09.030186.002041Open reference}0^{4Citation1986 · DOI 10.1146/annurev.ne.09.030186.002041Open reference}1

• Matrix-preferential degeneration: Within the striosome-matrix compartments, dopaminergic terminals in the matrix are more severely depleted than those in striosomes, particularly in the posterior putamen. This has implications for understanding why motor symptoms predominate over emotional/motivational symptoms in early PD.^{4Citation1986 · DOI 10.1146/annurev.ne.09.030186.002041Open reference}2

• DAT imaging: DAT-SPECT and 18F-DOPA PET reveal reduced putaminal uptake as the most sensitive imaging marker for PD diagnosis, typically showing asymmetric loss contralateral to the clinically more affected side

• Compensatory mechanisms: The remaining dopaminergic terminals in the putamen upregulate dopamine synthesis and release (increased dopamine turnover), contributing to the long presymptomatic phase. As these compensatory mechanisms fail, motor symptoms emerge

• Therapeutic target: The putamen is the primary target for levodopa therapy. Exogenous dopamine restores putaminal dopaminergic tone, rebalancing direct/indirect pathway activity. comt-inhibitors, mao-b-inhibitors, and dopamine-agonists all aim to enhance putaminal dopamine signaling. gene-therapy approaches delivering aromatic L-amino acid decarboxylase (AADC) directly to the putamen via stereotactic injection are in clinical trials, with promising Phase II results showing sustained improvement in 18F-DOPA uptake and motor scores

Huntington’s Disease

In huntington-pathway, the putamen undergoes severe neurodegeneration alongside the caudate-nucleus:

• medium-spiny-neurons of the indirect pathway (D2-expressing, enkephalin-positive) are lost first, contributing to early hyperkinetic chorea (loss of movement suppression)

• Later, direct pathway MSNs (D1-expressing, substance P-positive) are also lost, leading to the rigid-akinetic phenotype of advanced HD

• Putamen atrophy becomes significant approximately 3 years before estimated disease onset, later than caudate-nucleus atrophy, but putaminal atrophy rate accelerates as onset approaches^{4Citation1986 · DOI 10.1146/annurev.ne.09.030186.002041Open reference}3

• The mutant htt-protein (mHTT) forms intranuclear inclusions preferentially in MSNs, with striosome MSNs appearing to be more vulnerable than matrix MSNs in early disease stages

Multiple System Atrophy

In msa-P (parkinsonian subtype), the putamen is severely affected by alpha-synuclein glial cytoplasmic inclusions (GCIs) in oligodendrocytes, leading to putaminal degeneration and atrophy. MRI shows the characteristic “putaminal rim sign” — a hyperintense rim on T2-weighted imaging representing gliosis at the putaminal border — and putaminal atrophy, which can help distinguish MSA-P from PD. Longitudinal multi-center studies report annual putaminal atrophy rates of 4.2–8.2% in MSA, significantly exceeding rates in PD and healthy controls.^{4Citation1986 · DOI 10.1146/annurev.ne.09.030186.002041Open reference}4

Progressive Supranuclear Palsy

In progressive-supranuclear-palsy, the putamen shows tau/astrocytes and neurofibrillary tangles along with midbrain atrophy. Putaminal involvement contributes to axial rigidity and levodopa-unresponsive parkinsonism that characterize PSP.

Corticobasal Degeneration

corticobasal-degeneration features asymmetric putaminal atrophy contralateral to the affected limbs. tau-protein-positive astrocytic plaques and ballooned neurons are found in the putamen, contributing to the distinctive asymmetric akinetic-rigid syndrome with cortical features (apraxia, alien limb).

Other Conditions

• vascular-dementia: Lacunar infarcts in the putamen cause contralateral hemiparesis and may contribute to vascular parkinsonism. The putamen is the most common site of hypertensive basal ganglia hemorrhage

• wilson-disease: Copper deposition in the putamen causes the characteristic “face of the giant panda” sign on MRI and contributes to dystonia and parkinsonism

• nbia: Iron accumulation in the putamen and globus-pallidus causes the “eye of the tiger” sign in pantothenate kinase-associated neurodegeneration (PKAN)

• cte: Repetitive head trauma can lead to tau] pathology in the putamen, contributing to motor and behavioral symptoms

Therapeutic Relevance

Deep Brain Stimulation

While the subthalamic nucleus (STN) and GPi are the standard targets for deep-brain-stimulation in PD, the putamen is indirectly modulated by DBS. STN-DBS normalizes the pathologically increased activity of the indirect pathway, effectively restoring putaminal output balance. Neuroimaging studies show that effective DBS modulates functional connectivity involving the putamen, precuneus, and orbitofrontal cortex.^{4Citation1986 · DOI 10.1146/annurev.ne.09.030186.002041Open reference}5

Putamen-Targeted Gene Therapy

Direct infusion of viral vectors (AAV2-AADC, AAV2-GDNF) into the putamen via stereotactic neurosurgery represents a promising approach for PD. By delivering dopamine-synthesizing enzymes or neurotrophic-factors directly to the denervated putamen, these therapies aim to restore local dopaminergic function. Phase I/II trials of AAV2-AADC delivered to the putamen have shown sustained improvement in motor symptoms and increased 18F-DOPA uptake at the injection sites.

Pharmacological Targeting

Virtually all dopaminergic therapies for PD exert their primary therapeutic effect by modulating putaminal dopamine signaling:

• levodopa: Converted to dopamine by remaining putaminal terminals and non-dopaminergic cells

• dopamine-agonists: Directly stimulate D1/D2 receptors on putaminal MSNs

• mao-b-inhibitors: Reduce dopamine breakdown within the putaminal synaptic cleft

• comt-inhibitors: Prolong levodopa availability for conversion to dopamine in the putamen

• medium-spiny-neurons

• deep-brain-stimulation

External Links

• Allen Human Brain Atlas — Putamen Gene Expression

• BrainInfo — Putamen

Brain Atlas Resources

This section links to atlas resources relevant to this brain region.

• Allen Human Brain Atlas: Putamen expression search

• Allen Mouse Brain Atlas: Putamen search

• Allen Cell Type Atlas: Transcriptomic cell type reference

• BrainSpan Developmental Transcriptome: Putamen developmental expression

Background

The study of Putamen has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.